Antibodies
US9284376B2 · kind B2 · utility
0Cited by
20References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 20, 2011 |
| Grant date | Mar 15, 2016 |
| Priority date | — |
| Expiry date | Jul 27, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of VEGF antagonists and a novel anti-α5β1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-α5β1 antibodies and methods of making and using them.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.